Rosuvastatin + Placebo

Phase 3Completed

1 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Familial Hypercholesterolemia

Conditions

Familial Hypercholesterolemia

Trial Timeline

Jul 1, 2006 → Jul 1, 2008

NCT ID

NCT00355615

About Rosuvastatin + Placebo

Rosuvastatin + Placebo is a phase 3 stage product being developed by AstraZeneca for Familial Hypercholesterolemia. The current trial status is completed. This product is registered under clinical trial identifier NCT00355615. Target conditions include Familial Hypercholesterolemia.

What happened to similar drugs?

5 of 20 similar drugs in Familial Hypercholesterolemia were approved

Approved (5) Terminated (4) Active (13)

✅EvolocumabAmgenApproved

✅evolocumabAmgenApproved

✅AnakinraSwedish Orphan BiovitrumApproved

✅Colesevelam hydrochloride film-coated tablets + PlaceboSanofiApproved

✅PraluentSanofiApproved

🔄SHR-1209 ;placebo + SHR-1209 ;placebo + SHR-1209 ;placeboJiangsu Hengrui MedicinePhase 3

🔄Rosuvastatin 20mg + PlaceboAstraZenecaPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (11)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02546323	Phase 3	Completed	Sep 17, 2015	Jan 29, 2019	Atherosclerosis
NCT00929734	Phase 2	Completed	Mar 1, 2010	Jan 1, 2014	Chronic Obstructive Pulmonary Disease (COPD)
NCT00951132	Phase 2	Withdrawn	Sep 1, 2009	Dec 1, 2013	Depression
NCT00990028	Phase 1/2	Completed	Aug 1, 2009	Aug 1, 2011	Head Injury
NCT00783042	Phase 1	Completed	Oct 1, 2008	May 1, 2009	Atherosclerosis
NCT00673582	Approved	Terminated	Apr 1, 2008	Mar 1, 2013	Atherosclerosis
NCT00689416	Phase 1	Completed	Dec 1, 2007	Jun 1, 2009	Atherosclerosis
NCT00329758	Phase 2	Completed	Jul 1, 2006	Oct 1, 2007	Head Injury
NCT00355615	Phase 3	Completed	Jul 1, 2006	Jul 1, 2008	Familial Hypercholesterolemia
NCT00658463	Approved	Completed	Jan 1, 2006	Sep 1, 2007	Diabetes
NCT00800800	Phase 3	Completed	Nov 1, 2002	Sep 1, 2008	Aortic Stenosis

Competing Products

20 competing products in Familial Hypercholesterolemia

See all competitors

Product	Company	Stage	Hype Score
Bromocriptine Mesilate + Placebos	Towa Pharmaceutical	Phase 1/2	32
SHR-1209	Jiangsu Hengrui Medicine	Phase 2	31
SHR-1209 ;placebo + SHR-1209 ;placebo + SHR-1209 ;placebo	Jiangsu Hengrui Medicine	Phase 3	40
Rosuvastatin 20mg + Placebo	AstraZeneca	Phase 3	40
rosuvastatin calcium + rosuvastatin calcium + rosuvastatin calcium	AstraZeneca	Phase 3	40
Rosuvastatin 20mg	AstraZeneca	Phase 3	40
AZD0780 + Placebo	AstraZeneca	Phase 3	44
Anacetrapib + Placebo for anacetrapib	Merck	Phase 3	40
Statins and Ezetimibe	Merck	Pre-clinical	22
Comparator: niacin (+) laropiprant (MK0524A) + Comparator: placebo	Merck	Phase 3	32
MK-0524A + MK-0524A	Merck	Phase 1	21
Enlicitide Decanoate + Placebo	Merck	Phase 2/3	45
Inclisiran + Placebo	Novartis	Phase 3	40
DFV890	Novartis	Phase 2	35
Canakinumab	Novartis	Phase 2	35
Inclisiran Sodium for injection + Placebo + Placebos	Novartis	Phase 3	40
LCQ908 + Placebo	Novartis	Phase 3	40
Inclisiran	Novartis	Phase 3	44
Inclisiran + Placebo	Novartis	Phase 3	40
Fluvastatin	Novartis	Phase 3	40